Less than 30% of FDA-cleared AI devices shared key safety and adverse event data before approval, raising regulatory concerns.
Key Details
- 1A new analysis reviewed FDA approval and recall databases for all AI/ML devices cleared from 1995 to July 2023.
- 2Of 691 devices analyzed, 531 targeted radiology applications.
- 3Fewer than 30% of devices provided data on safety, efficacy, or adverse events prior to approval.
- 4No predefined efficacy or safety reporting standards currently exist for AI/ML devices in the U.S., unlike with pharmaceuticals.
- 5The findings highlight a regulatory gap and call for stricter testing and dedicated approval pathways for AI/ML-based medical devices.
Why It Matters
This research underscores a major gap in regulatory standards and transparency for AI devices in radiology, potentially impacting patient safety and trust. Addressing these concerns could lead to more robust evidence and safer adoption of AI in clinical imaging practice.
Source
Radiology Business
Related News
•AuntMinnie
AI Enables Safe 75% Gadolinium Reduction in Breast MRI Without Losing Sensitivity
AI-enhanced breast MRI with a 75% reduced gadolinium dose maintained diagnostic sensitivity comparable to full-dose protocols.
•Radiology Business
NVIDIA Envisions Autonomous AI Agents Transforming Radiology
NVIDIA foresees a major shift in radiology toward autonomous AI agents and imaging systems that could revolutionize patient care.
•Cardiovascular Business
Deep Learning AI Model Detects Coronary Microvascular Dysfunction Via ECG
A new AI algorithm rapidly detects coronary microvascular dysfunction using ECGs, with validation incorporating PET imaging.